MarketCapExport financials
Horizon Therapeutics Public Limited Company (HZNP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Horizon Therapeutics Public Limited Company Income Statement 2022-2008 | HZNP
Brief overview of income trends at Horizon Therapeutics Public Limited Company
This overview is based on financial performance over the past five years. Horizon Therapeutics Public Limited Company reported revenue of $1.1 billion in 2017 and $3.6 billion by 2022. Across the full period, sales moved by +243.6%; the average annual rate was 28%. The annual growth rate indicates an exceptionally strong top-line trend.
The gross result shifted from 563 million dollars to 2.7 billion dollars, or +381.3%. The cost base moved more slowly than the top line, which supported margins. At the margin level, the figure shifted from 53.3% to 74.6%. A wider margin shows that the economics of the core business improved.
EBITDA was −$83.4 million at the beginning and $1 billion at the end of the period (+1308.8%). Additional revenue translated efficiently into EBITDA. EBITDA margin moved from −7.9% to 27.8%. The increased EBITDA share is a positive sign.
The net financial result changed from −350 million dollars to 521 million dollars. The business moved out of a loss and ended the period with a profit.
Over the period, capitalization shifted from $2.4 billion to $25.2 billion (+959%). Investor expectations increased faster than reported performance.
Overall conclusion
The five-year financial profile is predominantly positive. The financial profile benefits from higher operating efficiency, improving gross profitability and a larger revenue base. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Horizon Therapeutics Public Limited Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
25.2 B | 24.3 B | 14.9 B | 6.62 B | 3.25 B | 2.38 B | 2.6 B | 3.22 B | 1.08 B | 485 M | 90.6 M | 36.1 M | - | - | - |
Shares |
229 M | 226 M | 204 M | 183 M | 166 M | 163 M | 161 M | 149 M | 83.8 M | 63.7 M | 38.9 M | 9.01 M | 1.28 M | - | - |
Historical Prices |
110 | 108 | 73.2 | 36.2 | 19.5 | 14.6 | 16.2 | 21.7 | 12.9 | 7.62 | 2.33 | 4 | - | - | - |
Net Income |
521 M | 534 M | 390 M | 573 M | -38.4 M | -350 M | -166 M | 39.5 M | -264 M | -149 M | -87.8 M | -113 M | -27.1 M | -20.5 M | - |
Revenue |
3.63 B | 3.23 B | 2.2 B | 1.3 B | 1.21 B | 1.06 B | 981 M | 757 M | 297 M | 103 M | 23 M | 6.94 M | 2.38 M | - | - |
Cost of Revenue |
920 M | 795 M | 533 M | 362 M | 391 M | 493 M | 392 M | - | - | - | - | - | - | - | - |
Gross Profit |
2.71 B | 2.43 B | 1.67 B | 938 M | 816 M | 563 M | 589 M | 538 M | 218 M | 59.4 M | 6.97 M | -340 K | -1.89 M | - | - |
Operating Income |
617 M | 543 M | 490 M | 127 M | 37.9 M | -339 M | -146 M | 55.4 M | -8.49 M | -42.9 M | -78.9 M | -121 M | -43.8 M | -18.8 M | - |
Interest Expense |
-5.57 M | 1.79 M | 3.39 M | -944 K | 841 K | 447 K | 6.7 M | -10.3 M | 23.8 M | 12.8 M | 11.6 M | 6.28 M | 3.02 M | 2.19 M | - |
EBITDA |
1.01 B | 897 M | 769 M | 364 M | 288 M | -83.4 M | 75.8 M | 194 M | 25.5 M | -33.5 M | -73.3 M | -116 M | -40.8 M | -18.7 M | - |
Operating Expenses |
2.09 B | 1.89 B | 1.18 B | 811 M | 778 M | 902 M | 735 M | 482 M | 227 M | 102 M | 85.8 M | 120 M | 41.9 M | 18.8 M | - |
General and Administrative Expenses |
1.54 B | 1.45 B | 973 M | 697 M | 692 M | 655 M | 288 M | 220 M | 89 M | 23.6 M | 19.4 M | 15 M | 18.6 M | 5.82 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Horizon Therapeutics Public Limited Company
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
229 M | 228 M | 227 M | 230 M | 230 M | 229 M | 227 M | 226 M | 225 M | 224 M | 221 M | 212 M | 193 M | 190 M | 188 M | 186 M | 185 M | 173 M | 169 M | 167 M | 166 M | 165 M | 164 M | 163 M | 163 M | 162 M | 162 M | 161 M | 160 M | 160 M | 160 M | 159 M | 151 M | 126 M | 124 M | 78.4 M | 73.4 M | 67.1 M | 66.1 M | 64.6 M | 62.9 M | 61.9 M | 61.7 M | 36 M | 33.7 M | 33.7 M | 19.6 M | 19.5 M | 1.5 M | 19.6 M |
Net Income |
127 M | 54.7 M | - | 136 M | 61 M | 204 M | - | 327 M | 158 M | -123 M | 191 M | 293 M | -80 M | -13.6 M | 593 M | 18.2 M | -5.12 M | -32.9 M | 102 M | 26 M | -32.8 M | -157 M | -38.2 M | -64 M | -210 M | -90.6 M | -131 M | -5.87 M | 15 M | -45.4 M | 24 M | 3.28 M | 31.8 M | -19.6 M | -31.6 M | 2.06 M | -27.8 M | -206 M | -103 M | -5.49 M | -18.4 M | -22.2 M | -24.3 M | -17 M | -22.8 M | -23.7 M | -76.7 M | -17.2 M | -11.6 M | -7.67 M |
Revenue |
945 M | 832 M | - | 925 M | 876 M | 885 M | - | 1.04 B | 833 M | 342 M | 745 M | 636 M | 463 M | 356 M | 364 M | 335 M | 321 M | 280 M | 356 M | 325 M | 303 M | 224 M | 274 M | 272 M | 290 M | 221 M | 310 M | 209 M | 257 M | 205 M | 245 M | 227 M | 173 M | 113 M | 104 M | 75.1 M | 66.1 M | 92.2 M | 30.1 M | 31.5 M | 17.6 M | 10.7 M | 6.36 M | 7.31 M | 4.61 M | 2.72 M | 3.53 M | 273 K | 1.34 M | 1.79 M |
Cost of Revenue |
220 M | 209 M | - | 234 M | 230 M | 215 M | - | 252 M | 201 M | 100 M | - | 151 M | 122 M | 97.4 M | - | 89.9 M | 89.2 M | 88.1 M | 98.6 M | 99 M | 100 M | 110 M | 143 M | 125 M | 130 M | 139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
725 M | 623 M | - | 691 M | 646 M | 670 M | - | 785 M | 632 M | 242 M | 583 M | 485 M | 341 M | 258 M | 269 M | 246 M | 231 M | 192 M | 257 M | 226 M | 203 M | 108 M | 131 M | 146 M | 159 M | 81.7 M | 161 M | 124 M | 176 M | 127 M | 177 M | 165 M | 111 M | 84.3 M | 71.2 M | 61.5 M | 41.3 M | 44.3 M | 24.8 M | 20.9 M | 8.74 M | 4.92 M | 2.82 M | 2.71 M | 986 K | 456 K | 1.45 M | -976 K | -769 K | -46 K |
Operating Income |
143 M | 36 M | - | 161 M | 88.6 M | 194 M | - | 332 M | 139 M | -160 M | 240 M | 229 M | 37.9 M | -16.5 M | 54.7 M | 48.6 M | 25.1 M | -1.8 M | 82.5 M | 54.2 M | 1.81 M | -127 M | -67.3 M | -25.8 M | -186 M | -105 M | -130 M | -21.3 M | 31.5 M | -27.2 M | 38 M | 45.7 M | -33.2 M | 4.76 M | 8.98 M | -12 M | -7.1 M | 1.59 M | -5.76 M | -2.74 M | -15.8 M | -18.5 M | -22 M | -18.7 M | -18.3 M | -19.8 M | -89.2 M | -15.7 M | -8.75 M | -6.99 M |
Interest Expense |
4.18 M | - | - | -2.28 M | -2.39 M | -742 K | - | -849 K | -262 K | 3.22 M | - | 717 K | 632 K | 442 K | - | 890 K | -1.27 M | 189 K | 8 K | 453 K | 347 K | 178 K | - | 280 K | -35 K | 35 K | - | 6.88 M | -26 K | -14 K | - | -90 K | 19.4 M | 10 M | - | 5.19 M | 4.21 M | 4.21 M | - | 3.6 M | 3.44 M | 3.6 M | - | 3.34 M | 3.19 M | 4.55 M | - | 995 K | 3.18 M | 1.28 M |
EBITDA |
334 M | 131 M | - | 452 M | 281 M | 289 M | - | 589 M | 301 M | -89.2 M | 240 M | 438 M | 177 M | 49.2 M | 54.7 M | 226 M | 143 M | 57.1 M | 82.5 M | 261 M | 139 M | -58.4 M | -67.3 M | 187 M | -42.7 M | -33.9 M | -130 M | 133 M | 134 M | 23.4 M | 38 M | 140 M | 17.6 M | 23.1 M | 8.98 M | 5.7 M | 3.74 M | 6.99 M | -5.76 M | 3.09 M | -11.9 M | -16.6 M | -22 M | -15.1 M | -16.2 M | -18.7 M | -89.2 M | -12.6 M | -6.7 M | -5.97 M |
Operating Expenses |
582 M | 588 M | - | 531 M | 558 M | 476 M | - | 454 M | 493 M | 402 M | - | 256 M | 303 M | 275 M | - | 197 M | 206 M | 194 M | 174 M | 172 M | 201 M | 235 M | - | 172 M | 345 M | 187 M | - | 145 M | 145 M | 155 M | - | 120 M | 144 M | 79.5 M | - | 73.4 M | 48.4 M | 42.7 M | - | 23.6 M | 24.5 M | 23.5 M | - | 21.4 M | 19.3 M | 20.2 M | - | 14.7 M | 7.98 M | 6.94 M |
General and Administrative Expenses |
434 M | 453 M | - | 398 M | 398 M | 373 M | - | 360 M | 355 M | 332 M | - | 226 M | 222 M | 248 M | - | 172 M | 167 M | 172 M | - | 162 M | 177 M | 180 M | - | 154 M | 182 M | 174 M | - | 59.5 M | 54 M | 66.4 M | - | 54.5 M | 77.2 M | 26.3 M | - | 38.1 M | 17.7 M | 11.2 M | - | 5.87 M | 5.18 M | 5.2 M | - | 4.68 M | 4.56 M | 5.2 M | - | 4.19 M | 3.35 M | 3.1 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Horizon Therapeutics Public Limited Company (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
